Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents ≥ 6 to <18 Years of Age
Pfizer
640 participants
Feb 28, 2022
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to \<18 years with episodic migraine.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Rimegepant 75mg or 50mg (2 X 25mg) ODT
Matching placebo 75mg or 50mg (2 X 25mg) ODT
Locations(93)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05156398